Regulated information

Get easy access to all the information you need. The documentation center allows you to open, send by e-mail or download any document. Feel free to use the filters and add several documents to your basket.

13 publications

Name	Date	Type
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.	29/04/2024	Public releases
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)	24/01/2024	Public releases
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.	26/10/2023	Public releases
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) Annual Sales of Essential products: €304 million (up 4.5% as reported)	18/01/2023	Public releases
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.	20/04/2023	Public releases
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) Essentials sales: €313m (+4.5% at constant exchange rates) Net income - Group share: €56m (10.5% of sales) EBITDA: €113m (21.3% of sales) Free cash-flow: €89m	20/03/2024	Public releases
Continued Sales Growth in the second Quarter of 2010 Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.	16/07/2010	Public releases
Continued sales growth driven by sustained organic growth April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.	22/04/2010	Public releases
Strong Sales in the 3rd Quarter of 2010 Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.	19/10/2010	Public releases
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) Essentials products sales: €151m (59% of Group sales) Net income - Group share: €32m (12.6% of sales) EBITDA*: €54m (20.9% of sales) Cash-flow generation: €31m	07/09/2023	Public releases